title: Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats.
abstract: A short-term exposure to resveratrol at high dosages exerts a remarkable cardioprotective effect. Whether a long-term exposure to resveratrol at low dosages that can be obtained through consumption of a resveratrol-rich diet is beneficial to heart diseases is unknown. We tested the effects of a resveratrol-enriched diet on cardiovascular remodeling of chronic heart failure (CHF) in rats resulting from permanent ligation of left coronary artery. Two weeks after surgery, rats were started on either a resveratrol-enriched (R; 5 mg/kg per day; n = 23) or normal (Control; n = 23) diet for next 10 months. Serial echocardiography in Control showed a significant decline in LV ejection fraction, increases in LV end-systolic and end-diastolic volumes, and expansion in myocardial infarct from pre-treatment values. In R, compared with Control, there were substantial improvements in those parameters. End-point LV pressure-volume loop analysis showed a significantly improved LV systolic function and AV-coupling, an index of energy transfer efficacy between the heart and aortic tree, in R compared with Control (p < 0.05). Aortic pulse wave velocity, a measure of arterial stiffness, was significantly lower in R (389 ± 15 cm/s; p < 0.05) compared with Control (489 ± 38 cm/s). These results demonstrated that long-term dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in CHF.
authors.affiliation: Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.|Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.
authors.forename: Ismayil
authors.initials: I
authors.lastname: Ahmet
authors.affiliation: Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.|Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.
authors.forename: Hyun-Jin
authors.initials: HJ
authors.lastname: Tae
authors.affiliation: Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.|Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.
authors.forename: Edward G
authors.initials: EG
authors.lastname: Lakatta
authors.affiliation: Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.|Laboratory of Cardiovascular Sciences, Intramural Research Program, NIA, NIH, Baltimore, MD 21224, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Talan
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004452:Echocardiography; D005355:Fibrosis; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D063177:Pulse Wave Analysis; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D059289:Vascular Stiffness / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D002316:Cardiotonic Agents; D013267:Stilbenes; D003094:Collagen; D000077185:Resveratrol
keywords: echocardiography; heart failure; insuffisance cardiaque; pulse wave velocity; remodelage; remodeling; resveratrol; resvératrol; vitesse des ondes pulsatiles; échocardiographie